Bexion Pharmaceuticals
Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.
Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.
Bexion Pharmaceuticals is a mid-stage clinical company focused on developing innovative treatments in Oncology and CNS. The company's lead compound, BXQ-350, is a novel S1P modulator with the potential to deliver breakthrough advancements in the field. With a strong emphasis on expertise in Oncology and a highly experienced biotech leadership team, the company is rapidly advancing its pipeline to bring about life-changing therapies in Oncology. Founded in 2006 and headquartered in the United States, Bexion Pharmaceuticals recently secured a notable $16.60M Series B investment on 30 April 2019. This investment signifies a pivotal moment for the company as it propels forward in its mission to become a leading biotech/pharmaceutical entity. For more information, visit Bexionpharma.com or call (859) 446-7386.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $16.60M | - | 30 Apr 2019 | |
| Seed Round | Unknown | 1 |
|
13 Nov 2008 |
No recent news or press coverage available for Bexion Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
